Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.48 |
| ▸ | MAOB | P27338 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527911 | 0.84 | MAOA (0.51) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL15629946 | 0.82 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1SMN1; SMN2PPARA | |
| SCHEMBL5543437 | 0.82 | MAOA (0.66) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL15444087 | 0.81 | POLB (0.40) | ALDH1A1SMN1; SMN2POLBPPARATHRB | |
| SCHEMBL527763 | 0.81 | MAOA (0.51) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL1035304 | 0.79 | POLB (0.52) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL7782068 | 0.79 | THRB (0.66) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL12389249 | 0.79 | THRB (0.56) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL16894509 | 0.78 | MAOA (0.54) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL21511969 | 0.78 | APP (0.51) | ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2597953-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | Inspire Pharmaceuticals, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20130131059-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2012015760-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131059-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING KINASE INHIBITOR COMPOUNDS IN PRODRUG FORMS | ROCK1, ROCK2, CIT | MAOA 342/4885MAOB 288/4885NPC1 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.